An Open-label Study to Investigate the Efficacy and Tolerability of Dapsone Gel, 7.5% in the Treatment of Acne Vulgaris in Men and Women With Skin of Color
Journal of Drugs in Dermatology · 2024
DOI: 10.36849/jdd.7897 ↗At a glance
Klinische Studie in Journal of Drugs in Dermatology, 2024. Written by Nour El-Kashlan and 6 co-authors. Major MEDLINE topics: Acne Vulgaris, Administration, Cutaneous, Dapsone, Severity of Illness Index. Cited 1 times so far (Crossref).
Abstract (original language)
INTRODUCTION: Acne vulgaris is a common skin disease prevalent in skin of color patients. Studies have demonstrated that dapsone gel, 7.5% (Aczone) used once daily is effective, safe, and well-tolerated for the treatment of acne in both men and women. However, minimal data are available in skin of color populations. This single-center, open-label clinical study investigated the efficacy and safety of dapsone gel, 7.5% in the treatment of moderate to severe acne vulgaris in patients with Fitzpatrick skin types IV-VI. METHODS: Twenty (20) adult subjects with moderate to severe acne and Fitzpatrick skin types IV-VI were enrolled in this study and treated with dapsone gel, 7.5% once daily for 24 weeks. RESULTS: Dapsone gel, 7.5% applied daily for 24 weeks reduced acne severity, post-inflammatory hyperpigmentation, and decreased new inflammatory and noninflammatory acne lesions in skin of color patients with moderate to severe acne vulgaris. Treatment resulted in improved acne health-related quality of life and patient symptoms related to acne, including patient-reported post-inflammatory hyperpigmentation, especially with a treatment duration of 18 weeks or longer. Limitations: The sample size was small and underpowered to detect statistically significant changes in some endpoints. CONCLUSION: Dapsone gel 7.5% was safe, well-tolerated, and efficacious in treating acne vulgaris and post-inflammatory hyperpigmentation in skin-of-color patients. Larger studies involving skin-of-color populations with acne vulgaris are warranted. J Drugs Dermatol. 2024;23(6):410-417. doi:10.36849/JDD.7897.
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
El-Kashlan, N., Cices, A., Kaufman, B., Da Rosa, J. C., Sanabria-Gonzalez, I., Khattri, S., & Alexis, A. (2024). An Open-label Study to Investigate the Efficacy and Tolerability of Dapsone Gel, 7.5% in the Treatment of Acne Vulgaris in Men and Women With Skin of Color. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.7897
Vancouver
El-Kashlan N, Cices A, Kaufman B, Da Rosa JC, Sanabria-Gonzalez I, Khattri S, et al. An Open-label Study to Investigate the Efficacy and Tolerability of Dapsone Gel, 7.5% in the Treatment of Acne Vulgaris in Men and Women With Skin of Color. Journal of Drugs in Dermatology. 2024. doi:10.36849/jdd.7897
BibTeX
@article{ElKashlan2024,
author = {El-Kashlan, Nour and Cices, Ahuva and Kaufman, Bridget and Da Rosa, Joel Correa and Sanabria-Gonzalez, Ingrid and Khattri, Saakshi and Alexis, Andrew},
title = {An Open-label Study to Investigate the Efficacy and Tolerability of Dapsone Gel, 7.5% in the Treatment of Acne Vulgaris in Men and Women With Skin of Color},
journal = {Journal of Drugs in Dermatology},
year = {2024},
doi = {10.36849/jdd.7897}
}
EUVIMED